Teng J, Imani S, Zhou A, Zhao Y, Du L, Deng S et al (2023) Combatting resistance: understanding multi-drug resistant pathogens in intensive care units. Biomed Pharmacother Biomedecine Pharmacother 167:115564. https://doi.org/10.1016/j.biopha.2023.115564

Article  CAS  Google Scholar 

Munier AL, Biard L, Legrand M, Rousseau C, Lafaurie M, Donay JL et al (2019) Incidence, risk factors and outcome of multi-drug resistant Acinetobacter baumannii nosocomial infections during an outbreak in a burn unit. Int J Infect Dis IJID off Publ Int Soc Infect Dis 79:179–184. https://doi.org/10.1016/j.ijid.2018.11.371

Article  Google Scholar 

Corcione S, Lupia T, De Rosa FG, Host and Microbiota Interaction Study Group (ESGHAMI) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) (2020) Microbiome in the setting of burn patients: implications for infections and clinical outcomes. Burns Trauma 8:tkaa033. https://doi.org/10.1093/burnst/tkaa033

Article  PubMed  PubMed Central  Google Scholar 

Parsels KA, Mastro KA, Steele JM, Thomas SJ, Kufel WD (2021) Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections. J Antimicrob Chemother 76(6):1379–1391. https://doi.org/10.1093/jac/dkab015

Article  CAS  PubMed  Google Scholar 

Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R et al (2021) Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 21(2):226–240. https://doi.org/10.1016/S1473-3099(20)30796-9

Article  CAS  PubMed  Google Scholar 

Mellon G, Clec’h C, Picard B, Cohen Y, Jauréguy F (2012) Postsurgical meningitis due to multiresistant Acinetobacter baumannii successfully treated with high doses of ampicillin/sulbactam combined with rifampicin and fosfomycin. J Infect Chemother 18(6):958–960. https://doi.org/10.1007/s10156-012-0404-9

Article  PubMed  Google Scholar 

Pasteran F, Cedano J, Baez M, Albornoz E, Rapoport M, Osteria J et al (2021) A new twist: the combination of Sulbactam/Avibactam enhances Sulbactam Activity against Carbapenem-Resistant Acinetobacter baumannii (CRAB) isolates. Antibiot (Basel) 10(5):577. https://doi.org/10.3390/antibiotics10050577

Article  CAS  Google Scholar 

Haley RW, Culver DH, White JW, Morgan WM, Emori TG, Munn VP et al (1985) The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals. Am J Epidemiol 121(2):182–205. https://doi.org/10.1093/oxfordjournals.aje.a113990

Article  CAS  PubMed  Google Scholar 

Smoke SM, Brophy A, Reveron S, Iovleva A, Kline EG, Marano M et al (2023) Evolution and transmission of Cefiderocol-Resistant Acinetobacter baumannii during an outbreak in the burn Intensive Care Unit. Clin Infect Dis off Publ Infect Dis Soc Am 76(3):e1261–e1265. https://doi.org/10.1093/cid/ciac647

Article  Google Scholar 

Wang M, Ge L, Chen L, Komarow L, Hanson B, Reyes J et al (2023) Clinical outcomes and bacterial characteristics of Carbapenem-resistant Acinetobacter Baumannii among patients from different global regions Clin Infect Dis. https://doi.org/10.1093/cid/ciad556

Paul M, Carrara E, Retamar P, Tängdén T, Bitterman R, Bonomo RA et al (2022) European Society of Clinical Microbiology and Infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect off Publ Eur Soc Clin Microbiol Infect Dis 28(4):521–547. https://doi.org/10.1016/j.cmi.2021.11.025

Article  CAS  Google Scholar 

Gill CM, Santini D, Takemura M, Longshaw C, Yamano Y, Echols R et al (2023 Apr) In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii. J Antimicrob Chemother. https://doi.org/10.1093/jac/dkad032

Pasteran F, Cedano J, Baez M, Albornoz E, Rapoport M, Osteria J et al (2021) A New Twist: The Combination of Sulbactam/Avibactam Enhances Sulbactam Activity against Carbapenem-Resistant Acinetobacter baumannii (CRAB) Isolates. Antibiotics (Basel). May https://doi.org/10.3390/antibiotics10050577

Rodriguez CH, Brune A, Nastro M, Vay C, Famiglietti A (2020 Jul) In vitro synergistic activity of the sulbactam/avibactam combination against extensively drug-resistant Acinetobacter baumannii. J Med Microbiol. https://doi.org/10.1099/jmm.0.001211

Tiseo G, Giordano C, Leonildi A, Riccardi N, Galfo V, Limongi F et al (June 2023) Salvage therapy with sulbactam/durlobactam against cefiderocol-resistant Acinetobacter baumannii in a critically ill burn patient: clinical challenges and molecular characterization. JAC-Antimicrobial Resist 5. https://doi.org/10.1093/jacamr/dlad078